R&D channel feed

Im­bria touts PhII suc­cess in hy­per­trophic car­diomy­opa­thy, adding fu­el to over­all ef­fi­ca­cy pro­file

Last year

Gilead, Ar­cus’ PhII gas­troe­sophageal can­cer da­ta ar­gue for TIG­IT an­ti­body drug class po­ten­tial

Last year

Ven­tyx Bio­sciences' stock drops over 70% af­ter ax­ing pso­ri­a­sis drug pro­gram

Last year

No­var­tis slots PhI car­dio­vas­cu­lar can­di­date in­to pipeline, pay­ing Ko­re­an part­ner $80M up­front

Last year
Deals

Ver­tex dis­con­tin­ues a PhII rare dis­ease drug, sets ear­ly 2024 time­line for piv­otal non-opi­oid pain pill read­out

Last year
Pharma

Ko­di­ak 're­boot­s' Eylea com­peti­tor af­ter pos­i­tive da­ta in di­a­bet­ic vi­sion loss tri­al

Last year

Moon­Lake’s stock falls more than 20% de­spite mid-stage suc­cess in pso­ri­at­ic arthri­tis

Last year

RAPT Ther­a­peu­tics bol­sters part­ner search with PhII da­ta on small mol­e­cule-Keytru­da com­bo

Last year

As­traZeneca, Ele­don and Alpine spell out kid­ney pro­gram suc­cess­es: ASN roundup

Last year

Pfiz­er to cut 200 jobs at Michi­gan plant that makes Covid prod­ucts

Last year
People
Pharma

In ear­ly look at ASH ab­stracts, BeiGene touts Brukin­sa da­ta, Cel­lec­tis com­pares in-house CAR-T to CD­MO CAR-T

Last year

Boehringer In­gel­heim plans PhI­II chron­ic kid­ney dis­ease tri­al for al­dos­terone-tar­get­ing drug af­ter mid-stage suc­cess

Last year

Kro­nos Bio ax­es near­ly one-fifth of staff to pre­serve cash for two can­cer pro­grams

Last year
People

In­tel­lia sug­gests AT­TR amy­loi­do­sis gene edit­ing treat­ment has over a year of dura­bil­i­ty as it gears up for PhI­II

Last year
Cell/Gene Tx

Seres Ther­a­peu­tics sheds about 160 jobs to fo­cus on com­mer­cial C. diff pill

Last year
People

Mede­or’s cell ther­a­py boosts im­mune tol­er­ance in reg­is­tra­tional tri­al of donor kid­ney re­cip­i­ents

Last year
Cell/Gene Tx

Up­dat­ed: Eli Lil­ly's Moun­jaro sales hit $1.4B for the quar­ter, but FDA de­ci­sion on Alzheimer's drug is de­layed

Last year

Ro­bot­ic pill mak­er Rani paus­es pro­grams, cuts head­count to ex­tend cash run­way through 2025

Last year
People

Sang­amo lays off 160+ staffers, winds down fa­cil­i­ty, punts clin­i­cal pro­grams in dras­tic re­vamp

Last year
People

Si­lence un­veils more PhI da­ta for siR­NA drug in new car­dio­vas­cu­lar race tar­get­ing Lp(a)

Last year

Af­ter the ap­plause: New ef­fi­ca­cy ex­pec­ta­tions in urothe­lial can­cer af­ter Pad­cev-Keytru­da da­ta re­veal

Last year
Pharma
In Focus

GSK touts Arexvy sales as it dom­i­nates US old­er adult RSV mar­ket, com­pa­ny cuts three ear­ly-stage as­sets

Last year
Pharma

Ver­tex doesn’t need to do more test­ing for rogue gene ed­its from sick­le cell ther­a­py tri­al, FDA ad­vi­sors say

Last year
FDA+

Long­time can­cer R&D chief Pe­ter Lebowitz is tak­ing his fi­nal bows at J&J on­col­o­gy. Now what?

Last year
Bioregnum
First page Previous page 62636465666768 Next page Last page
A service from the Financial Times